U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications

Communications in Clinical Cytometry

Volumn 30, Issue 5, 1997, Pages 249-263

  Davis, Bruce H ^a   Foucar, Kathy ^b   Szczarkowski, Wlodek ^c   Ball, Edward ^d   Witzig, Tom ^e   Foon, Kenneth A ^f   Wells, Denise ^g   Kotylo, Pat ^h   Johnson, Rebecca ⁱ   Hanson, Curtis ^e   Bessman, David ^j  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Cytometry Associates Inc   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g HEMATOLOGICS INC   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ BERKSHIRE MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CONFERENCE PAPER; FLOW CYTOMETRY; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOMA; MINIMAL RESIDUAL DISEASE; NEOPLASM; PRIORITY JOURNAL; TREATMENT INDICATION; UNITED STATES;

CANADA; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOMA; UNITED STATES;

EID: 0345485136     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19971015)30:5<249::AID-CYTO6>3.0.CO;2-C     Document Type: Conference Paper

References (175)

1. Adriaansen H, Jacobs B, Kappers-Klunne M, Hahlen K, Hooijkaas H, Van Dongen J: Detection of residual disease in AML patients by use of double immunologic marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 7:472-479, 1993.
2. Adriaansen H, Van Dongen J, Kappers-Klunne M, Hahlen K, Van't Veer M, Wijdenes de Bresser J, Holdrinet A, Harthoorn-Lasthizen E, Abels J, Hooijkaas H: Terminal deoxynucleotidyl transferase positive subpopulations occur in the majority of ANLL: Implications for the detection of minimal disease. Leukemia 4:404-411, 1990.
3. Ball E: Immunophenotyping of acute myeloid leukemia cells. Clin Lab Med 10:721-736, 1990.
4. Banks P: Technical aspects of specimen preparation and special studies. In: Surgical Pathology of the Lymph Nodes and Related Organs, 2nd ed., Jaffe ES (ed). W.B. Saunders Co., Philadelphia, 1995, pp 1-21.
5. Batata A, Shen B: Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia. A study of 242 cases. Cancer 70:2436-2443, 1992.
6. Beck W, Grogan T, Willman C, Cordon-Cardo C, Parham D, Kuttesch J, Andreef M, Bates S, Berard C, Boyett J, Brophy N, Broxterman H, Chan H, Dalton W, Dietel M, Fojo A, Gascoyne R, Head D, Houghton P, Srivastava D: Methods to detect P-Glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 56:3010-3020, 1996.
7. Behm F, Raimondi S, Schell M, Look A, Rivera G, Pui C: Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood 79:1011-1016, 1992.
8. Behm F, Smith F, Raimondi S, Head D, Downing J, Bernstein I: Blasts of childhood acute lymphoblastic leukemia with translocations and inversions of chromosome 11q express a unique surface protein identified by MoAb 7.1. Mod Pathol 7:102a, 1994.
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox L: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French American British Cooperative Leukaemia Group. Br J Haematol 87:746-754, 1994.
10. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78:325-329, 1991.
11. Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weidner P, Buckner C: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158-3167, 1993.
12. Boccadoro M, Marmont F, Tribalto M, Fossati G, Avvisati G, Andriani A. Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F, Frieri R, Gallamini A, Gallone G, Giovangrossi P, Grignani F, Lauta V, Liberati M, Musto P, Neretto G: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisonc even in high-risk patients. Journal of Clinical Oncology 9:444-448, 1991.
13. Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, Battaglio S, Massaia M, Gallamini A, Comotti B, Barbui T, Campobasso N, Dammacco F, Cantonetti M, Petrucci M, Mandelli F, Resegotti L, Pileri A: Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 7:119-125, 1989.
14. Bogen S, Pelley D, Charif M, McCusker M, Koh H, Foss F, Garifallou M, Arkin C, Zucker-Franklin D: Immunophenotypic identification of Sezary cells in peripheral blood. Amer J Clin Path 106:739-748, 1996.
15. Borowitz M, Guenther K, Shults K, Steltzer G: Immunophenotyping of acute leukemia by flow cytometric analysis. Amer J Clin Pathol 100:534-540, 1993.
16. Borowitz M, Shuster J, Carroll A, Nash M, Look A, Camitta B, Mahoney D, Lauer S, Pullen D: Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group study. Blood 89:3960-3966, 1997.
17. Bradstock K, Matthews J, Benson E, Page F, Bishop J, Australian Leukaemia Study Group: Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 84:1220-1225, 1994
18. Brugger W, Bross K, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636-642, 1994.
19. Burke M: Clinical laboratory consultation. Clin Chem 41:1237-1240, 1995.
20. Burke M: The future of clinical pathology. Arbiter of quality and gatekeeper of laboratory resources. Am J Clin Pathol 103:121-122, 1995.
21. Campana D: Applications of cytometry to study acute leukemia: In vitro determination of drug sensitivity and detection of minimal residual disease, Cytometry 18:68-74, 1994.
22. Campana D, Freitas R, Coustan-Smith E: Detection of residual leukemia with immunologic methods: Technical developments and clinical implications. Leuk Lymphoma 13:31-34, 1994.
23. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416-1434, 1995.
24. Carolli G, Gianfaldoni M, Azzara A: FcRIII (CD16) Expression on neutrophils from chronic myeloid leukemia. A flow cytometric study. Leuk Res 16:1203-1209, 1992.
25. Catovsky D: Chronic lymphoproliferative disorders. Curr Opin Oncol 7:3-11, 1995.
26. Chang H, Tien H, Wang C: Comparison of clinical and biologic-features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 71:87-93, 1993.
27. Cheson B, Bennett J, Grover M, Kay N, Keating M, O'Brien S, Rai K: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996.
28. Civin C, Loken M: Cell Surface Antigens on Human Marrow Cells: Dissection of Hematopoietic Development Using Monoclonal Antibodies and Multiparameter Flow cytometry. In Concise Reviews in Clinical and Experimental Hematology. Murphy M (ed), AlphaMed Press, Dayton, OH, 1992,
29. Civin C, Strauss L, Brovall C, Fackler M, Schwartz J, Shaper J: Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 133:157-165, 1984.
30. Clark R, Smith S, Jacobs A: Myeloid surface antigen abnormalities in myelodysplasia: Relation to prognosis and modification by 13-cis retinoic acid. J Clin Pathol 40:652-656, 1987.
31. Copelan E, McGuire A: The biology and treatment of ALL in adults. Blood 85:1151-1168, 1995.
32. Cornelissen J, Sonneveld P, Schoester M, Raaijmakers H, Nieuwenhuis H, Dekker A, Lokhorst H: MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myelom refractory to alkylating agents. J Clin Oncol 12:115-119, 1994.
33. Coustan-Smith E, Behm F, Hurwitz C, Rivera G, Campana D: N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 7:853-858, 1993.
34. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmerman M, Loffler H, Riehm H, Schellong G, Ludwig W-D: Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood 86:3097-3108, 1995.
35. Cuneo A, Michaux JL, Ferrant A, Van Hove L, Bosly A, Stul M, Dal Cin P, Vandenberghe E, Cassiman JJ, Negrini M: Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers. Blood 79:720-727, 1992.
36. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G: Prognostic value of cell marker analysis in de novo acute myeloid leukemia, Leukemia 8:388-384, 1994.
37. Derderian P, Kantarjian H, Talpaz M, O'Brien S, Cork A, Estey E, Pierce S, Keating M: Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69-74, 1993.
38. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734, 1992.
39. Drach J, Gattringer C, Huber H: Combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in acute leukemia. Br J Haematol 77:37-43, 1991
40. Durie B, Salmon S, Moon T: Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55:364-372, 1980.
41. Eaves C: Peripheral blood stem cells reach new heights, Blood 82:1957-1959, 1993.
42. Eisterer W, Hilbe W, Studer R, Bechter O, Fend F, Thaler J: An aggressive subtype of B-CLL is characterized by strong CD44 expression and lack of CD11c. Brit J Haematol 93:661-669, 1996.
43. Emile J-F, Bouliand M-L, Haloun C, Kanavaros P, Petrella T, Delfau-Larue M-H, Bensussan A, Farcet J-P, Gaulard P: CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87:1466-1473, 1996.
44. Fagioli F, Cunco A, Bardi A: Heterogeneity of lineage involvement by trisomy 8 in myelodysplastic syndrome. Cancer Genet Cytogenet 82:116-122, 1995.
45. Felmann T, Gisslinger H, Ludwig H: Imnunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma 15:201-208, 1994.
46. Finn W, Thangavelu M, Yelavarthi K, Goolsby C, Tallman M, Traynor A, Peterson L: Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 105:458-467, 1996.
47. Forehead N, Lens D, Zonas A, Merely R, Matutes E, Catovsky D: Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br J Haematol 91:640-646, 1995.
48. Geisler C, Larsen J, Hansen N, Hansen M, Christensen B, Lund B, Neilsen H, Plesenr T, Thorling K, Andersen E, Andersen P: Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 78:1795-1802, 1991.
49. Goasguen J, Dossot J, Fardel O, Le Mee F, Lee Gall E, Leblay R, Leprise P, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications, Blood 81:2394-2399, 1993.
50. Gorin N-C, Lopez M, Laporte J-P, Quittet P, Lesage S, Lemoine F, Berenson R, Isnard F, Grande M, Stachowiak J, Labopin M, Fouillard L, Morel P, Jouet J-P, Noel-Walter M-P, Detourmignies L, Aoudjhane M, Bauters F, Najman A, Douay L: Preparation and successful engraftment of purified CD34- bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 85:1647-1654, 1995.
51. Greipp P, Katzmann J, O'Fallon W, Kyle R: Value of b2 microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72:219-223, 1988.
52. Greipp P, Lust J, O'Fallon W, Katzmann J, Witzig T, Kyle R: Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993.
53. Greipp P, Oken M, Kalish L, Miller A, Kyle R: Independent prognostic value for plasma cell labeling index (PCLI) and beta 2-microglobulin (B2-M) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487. Proc Amer Soc Clin Oncol 11:357-363, 1992.
54. Guyotat D, Campos L, Thomas X: Myelodysplastic syndromes: A study of surface markers and in vitro growth patterns. Am J Hematol 34:26-31, 1990.
55. Hanson C, Abaza M, Sheldon S, Ross C, Schnitzer B, Stoolman L: Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis. Br J Haematol 84:49-60, 1993
56. Hanson C, Schnitzer B: Flow cytometric analysis of cytologic-specimens in hematologic diseases. J Clin Lab Anal 3:2-7, 1989.
57. Harada H, Kawano M, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81:2658-2663, 1993.
58. Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, Delsol G, De Wolf-Peeter C, Falini B, Gatter K, Grogan T, Isaacson P, Knowles D, Mason D, Muller-Hermelink H-K, Pileri S, Piris M, Ralkiaer E, Warnke R: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
59. Hill R, Goodale F: The Delphi predictions of pathology chairmen: A six-year retrospective view. J Med Educ 56:537-546, 1981.
60. Hoyer J, Ross C, Li C-Y, Witzig T, Gascoyne R, Dewald G, Hanson C: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 86:1163-1169, 1995.
61. Hurwitz C, Loken M, Graham M, Karp J, Borowitz M, Pullen D, Civin C: Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 72:299-307, 1988.
62. Hurwitz C, Raimondi S, Head D, Drance R, Mirro JJ, Kalwinshy D, Ayers G, Behm F: Distinctive immunophenotypic features of t(8; 21 )(q22q22) acute myeloblastic leukemia in children. Blood 80:182-188, 1992.
63. Inger M, Hokland P: The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br J Haematol 87:477-482, 1994.
64. Janossy G, Coustan-Smith E, Campana D: The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: A study of 500 cases. Leukemia 3:170-179, 1988.
65. Kabutomori O, Iwatani Y, Koh T, Yanagihara T: CD16 antigen density on neutrophils in chronic myeloproliferative disorders. Am J Clin Pathol 107:661-664, 1997.
66. Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz, M: Chronic myelogenous leukemia: A concise update. Blood 82:691-703, 1993.
67. Katz R, Raval P, Manning J: A morphologic, immunologic, and cytometric approach to the classification of non-Hodgkin's lymphoma in effusions Diagn Cytopathol 3:91-101, 1987.
68. Kawano M, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A: Identification of immature and mature myeloma cells in the hone marrow of human myelomas. Blood 82:564-570, 1993.
69. Keichle F, Chambers L, Cox R, Davis B, Davis C, Farkas D, Fink L, Kaul K, Wiedbrauk D (eds): Reference Guide to Diagnostic Molecular Pathology and Flow Cytometry. Northfield IL: College of American Pathologists, 1996.
70. Kendrup G, Bendix-Hansen K, Pedersen B: Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data. Eur J Haematol 41:368-374. 1988.
71. Kessinger A, Armitage J, Smith D, Landmark J, Bierman P, Weisenburger D: High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74:1260-1265, 1989.
72. Kibbelaar R, van Kamp H, Dreef E, de Groot-Swings G, Kluin-Nelemans J, Beverstock G, Fibbe W, Kluin P: Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79:1823-1828, 1992.
73. Kilo M, Dorfman D: The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 105:451-457, 1996.
74. Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi I, Shirakawa S, Tanaka I, Ohta C, Tsutani H, Oguma S: Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 81:2399-2405, 1993.
75. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, Takakura N, Otsuji A, Shirakawa S, Ueda T: Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 80:470-477, 1992.
76. Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R: Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59:43-51, 1982.
77. Launder T, Bray R, Stempora L, Chenggis M, Farhi D: Lymphoid-associated antigen expression by acute myeloid leukemia. Amer J Clin Path 106:185-191, 1996
78. Lavabre-Bertrand T, Poncelet P, Janossy G: Antigen density evaluation is a useful parameter in leukemia monitoring Leuk Lymphoma 13:118-123, 1994.
79. Leith C, Chen I-M, Kopecky K, Appelbaum F, Head D, Godwin J, Weick J. Willman C: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/Efflux+ and MDR1+/Efflux- cases. Blood 86:2329-2342, 1995.
80. Leslie D, Johnston W, Daly L, Ring D, Shpall E, Peters W, Bast R: Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 94:8-14, 1990.
81. Letwin B, Wallace P, Muirhead K, Hensler W, Kashatus W, Horan P: An improved clonal excess assay using flow cytometry and B cell gating. Blood 75:1178-1185, 1990.
82. Lima M, Teixeira M, Morais S: Immunophenotypic characteristics of acute leukemia after myelodysplastic syndromes. Sangre 40:49-52, 1995.
83. Little J, Foucar K, Horvath Z, Crago S: Flow cytometric analysis of lymphoma and lymphoma-like disorders. Semin Diagn Pathol 6:37-54, 1989.
84. Loken M, Shah V, Datilia K, Civin C: Flow cytometric analysis of human hone marrow: II. Normal B lymphoid development Blood 70:1316, 1987.
85. Loken M, Terstappen L, Civin C, Fackler M: Flow cytometric characterization of erythroid, lymphoid and monomyeloid lineages in normal human hone marrow. In O Laenum and R Bjerknes (eds), Flow Cytometry in Hematology. New York, Academic Press, 1992.
86. Loughran T: Clonal disease of large granular lymphocytes. Blood 82:1-14, 1993.
87. Macedo A, Orfao A, Vidrailes M, Lopez Berges M, Valverde B, Gonzalez M, Caballero M, Ramos F, Martinez M, Fernandes Calvo J: Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 70:189-194, 1995.
88. Macon W, Williams M, Greer J, Hammer R, Glick A, Collins R, Cousar J: Natural killer-like T cell lymphomas: Aggressive lymphomas of T-large granular lymphocytes. Blood 87:1474-1483, 1996.
89. Madeiros L, Picker L, Gelb A, Weiss L, Warnke R: Well-differentiated lymphocytic neoplasms: Immunologic findings correlated with clinical presentation and morphologic features. Am J Pathol 129:523-535, 1987.
90. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Scmpere A, Catovsky D: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia: Clinical and immunologic characterization. Blood 78:3269-3274, 1991.
91. Matutes E, Catovsky D: CLL should be used only for the disease with B-cell phenotype. Leukemia 6:917-919, 1993.
92. Matutes E, Catovsky D: Mature T-cell leukemias and leukemia/ lymphoma syndromes. Review of our experience in 175 cases. Leuk Lymph 4:81-91, 1991.
93. Matutes E, Catovsky D: The value of scoring systems for the diagnosis of hiphenotypic leukemia and mature B-cell disorders Leuk Lymphoma 13:11-14, 1994.
94. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D: The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 83:1558-1562, 1994.
95. Matutes E, Owusu-Ankomah K, Morilla R, Garcia-Marco J, Houlihan A, Que T, Catovsky D: The immunologic profile of B cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994.
96. Metter G: Morphologic classification of follicular lymphoma. Variability of diagnosis among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol 3:25-28, 1985.
97. Miwa H, Kita K, Nishii K, Monta N, Ohishi K, Mahmud N, Kageyama S, Fukumoto M, Shirakawa S: Expression of MDRI gene in acute leukemia cells: Association with CD7+ acute myeloblastic leukemia/ acute lymphoblastic leukemia. 82:3445-3451, 1993.
98. Molino A, Colombatti M, Bonetti F, Zardini M, Pasini F, Perini A, Pelosi G, Tridente G, Veneri D, Cetto G: A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer 67:1033-1038, 1991.
99. Montecucco C, Riccardi A, Ucci G, Danova M, Carnevale R, Caporali R: Analysis of human myeloma cell population kinetics. Acta Haematol 75:153-156, 1986.
100. Moss T, Sanders D, Lasky L, Bostrom B: Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells Blood 76:1879-1884, 1987.
101. Murakami T, Ohyashiki K, Ohyashiki J: Cytogenetic and immunogenetic alterations of blast crisis cells in chronic myelogenous leukemia independently linked to immunophenotypic expression. Cancer Genet Cytogenet 72:48-54, 1994.
102. Nowak R, Oelschlaegel U, Zengler H, Hofmann R, Ehninger G, Andreeff M: Sensitivity of combined DNA/Immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in hone marrow. Cytometry 30:47-53, 1997.
103. Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Becken B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W: P-glycoprotein expression in patients with acute leukemia - clinical experience. Leukemia 10:S23-S31, 1996.
104. Oertel J, Huhn D: CD34 immunophenotyping of blasts in myelodysplasia. Leuk Lymphoma 15:65-69, 1994.
105. Oertel J, Kleirer S, Huhn D: Immunotyping of blasts in refractory anaemia with excess blasts Br J Haematol 84:305-309, 1993.
106. Ohyashiki J, Ohyashiki K, Kawakubo K: Comparison between immunogenotypic findings in de novo AML, and AML post MDS. Leukemia 7:1747-1751, 1993.
107. Okuno S, Tefferi A, Hanson C, Katzmann J, Li C, Witzig T: Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Brit J Haematol 93:810-816, 1996.
108. Orazi A, Neiman R, Cualing H: CD34 immunostaining of bone-marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia. Am J Clin Pathol 101:426-428, 1994.
109. Paietta E, Andersen J, Wiernik P: A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Leukemia 10:1-4, 1996.
110. Pearson L, Leith C, Duncan M, Chen I-M, McConnell T, Trinkaus K, Foucar K, Willman C: Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8:21) chromosomal translocation in pediatric acute myeloid leukemia Leukemia 10:1274-1281, 1996.
111. Pettengell R, Testa N, Swindell R, Crowther D, Dexter T: Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 82:2239-2243, 1993.
112. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Goldstone A, Burnett A: Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8:21). Blood 87:1162-1169, 1996.
113. Pui C, Behm F, Crist W: Clinical and biological relevance of immunologic marker studies in childhood ALL. 82:383-362, 1993.
114. Pui C, Hancock M, Head D, Rivera G, Look A, Sandlund J, Behm F: Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 82:889-894, 1993.
115. Raife T, Lager D, Kemp J, Dick F: Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. Am J Clin Pathol 101:296-269, 1994.
116. Rainer R, Hodges L, Stelzer G: CD45 gating correlates with bone marrow differential. Cytometry 22:139-145, 1995.
117. Reading C, Estey E, Huh Y, Claxton D, Sanchez G, Terstappen L, O'Brien M, Baron S, Deisseroth A: Expression of unusual immunophenotype combinations in acute myelogeneous leukemia. Blood 81: 3083-3090, 1993.
118. Ribrag V: Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia 10:1944-1949, 1996.
119. Robbins B, Ellison D, Spinosa J, Carey C, Lukes R, Poppema S, Saven A, Piro L: Diagnostic Application of Two-Color Flow Cytometry in 161 Cases of Hairy Cell Leukemia. Blood 82:1277-1287, 1993.
120. Robertson L, Huh Y, Butler J, Pugh W, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating M: Response Assessment in Chronic Lymphocytic Leukemia After Fludarabine Plus Prednisone: Clinical, Pathologic, Immunophenotypic, and Molecular Analysis. Blood 80:29-36, 1992.
121. Robins D, Katz R, Swan F, Atkinson E, Ordonez N, Huh Y: Immunophenotyping of lymphoma by fine-needle aspiration. A comparative study of cytospin preparations and flow cytometry. Am J Clin Pathol 101:569-576, 1994.
122. Ross A, Cooper B, Lazarus H, Mackay W, Moss T, Ciobanu N, Tallman M, Kennedy M, Davidson N, Sewwt D, Winter C, Akard L, Jansen J, Copelan E, Meagher R, Herzig R, Klumpp T, Kahn D, Warner N: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2613, 1993.
123. Ross D, Brunning R, Kantarjian H: A proposed staging system for chronic myeloid leukemia. Cancer 71:3788-3791, 1993.
124. Rozman C, Monterrat E: Current concepts: Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057, 1995.
125. Ruiz-Argüelles G, San Miguel J: Cell surface markers in multiple myeloma. Mayo Clinic Proceedings 69:684-690, 1994.
126. Sainati L, Matutes E, Mulligan S, Catovsky D: A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 76:157-162, 1990.
127. San Miguel J, García-Sanz R, González M, Moro M, Hernández J, Ontega F, Borrego D, Carnera M, Casanova F, Jiménez R, Portero J, Orfao A: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448-455, 1995.
128. Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H, Koizumi K. Yasukouchi T, Yamaguchi M, Kaike T: Proliferation and differentiation of myelodysplastic CD34+ cells: Phenotypic subpopulations of marrow CD34+ cells Blood 85:194-202, 1995.
129. Sawada K, Sato N, Tarumi T: Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: Response to individual colony-stimulating factors. Br J Haematol 83:349-358, 1993
130. Schneider E, Cowan K, Bader H, Toomey S, Schartz G, Karp J, Burke P, Kaufmann S: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186-193, 1995.
131. Segal G, Edinger M, Owen M, McNealis M, Lopez P, Perkins A, Linden M, Fishleder A, Stoler M, Tubbs R: Concomitant delineation of surface Ig, B-cell differentiation antigens, and HLA-DR on lymphoid proliferation using three-color immunocytometry. Cytometry 12:350-359, 1991.
132. Seivers E, Lange B, Buckley J, Smith F, Wells D, Daigneault-Creech C, Shults K, Bernstein I, Loken M: Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry J Natl Cancer Inst 88:1483-1488, 1996.
133. Sememzato G, Zambello R, Starkebaum G, Oshimi K, Loughran T: The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood 89:256-260, 1997.
134. Sharp J, Joshi S, Armitage J, Bierman P, Coccia P, Harrington D, Kessinger A, Crouse D, Mann S, Weisenburger D: Significance of detection of occult non-Kodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 79:1074-1080, 1992.
135. Sharp J, Kessinger A, Mann S, Crouse D, Dicke J, Masih A, Weisenberger D: Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 10(suppl 1):92-97, 1992
136. Shpall EJ, Clark-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Jr., Ross M, Lidor Y: High dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386-391, 1990.
137. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern A, Lansdorp P, Bonadonna G, Gianni A: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991.
138. Sievers E, Loken M: Detection of minimal residual disease in acute myelogenous leukemia. J. Ped Hem/Onc 17:123-133, 1995.
139. Simpson S, Vachula M, Kennedy M, Kaizer H, Coon J, Ghalie R, Williams S. Van Epps D: Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 23:1062-1068, 1995.
140. Smith F, Lampkin B, Versteeg C, Flowers D, Dindorf P, Buckley J, Woods W, Hammond G, Bernstein I: Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood 79:2415-2422, 1992.
141. Smith M, Mohamed A, Karanes C: CD7+TDT+ chronic myelogenous leukemia blast crisis with null genotype. Leukemia 7:177-180, 1993.
142. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G: Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-MO). Blood 83:1619-1625, 1994.
143. Stetler-Stevenson M, Mederios J, Jaffe E: Immunophenotypic methods and findings in the diagnosis of lymphoproliferative diseases. In: Surgical Pathology of the Lymph Nodes and Related Organs, Second Edition, Jaffe ES (ed). Philadelphia: W.B Saunders Co., 1995. p. 22-57.
144. Sullivan S, Marsden K, Lowenthal R: Circulating CD34+ cells: An adverse prognostic factor in the myelodysplastic syndromes. Am J Hematol 39:96-101, 1992.
145. Syrjala M, Anttila V, Ruutu T, Jansson S: Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia 8:1564-1570, 1994.
146. te Boekhorst P, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P: Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157-3162, 1993.
147. Tefferi A, Bartholmai B, Witzig T, Li C-Y, Hanson C, Phyliky R: Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 106:457-461, 1996.
148. Terstappen L, Hollander Z, Meiners II, Loken M: Quantitative comparison of myeloid antigens; on five lineages of mature peripheral blood cells. J Leuk Biol 48:138-148, 1990.
149. Terstappen L, Johnsen S, Segers-Nolten I, Loken M: Identification and characterization of plasma cells in normal human hone marrow by high-resolution flow cytometry. Blood 76:1739-1747, 1990.
150. Terstappen L, Konemann S, Safford M, Loken M, Zurlutter K, Buchner T, Hiddemann W, Wormann B: Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties. Leukemia 5:315-321, 1991.
151. Terstappen L, Konemann S, Safford M, Loken M, Zurlutter K, Buchner T, Hiddemann W, Wormann B: Flow cytometric characterization of Acute Myeloid Leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 6:70-80, 1991.
152. Terstappen L, Loken M: Leukocyte differential counting. In: Flow Cytometry in Hematology, O Laerum, R Bjerknes, (eds). San Diego: Academic Press, 1992, pp. 95-110.
153. Terstappen L, Loken M: Multi-dimensional flow cytometric characterization of myeloid maturation in normal bone marrow and acute myeloid leukemia In: Advances in Analytical Cellular Pathology, G Burger, M Oberholzer, G Vooijs (Eds). Amsterdam: Excerpta Medica, 1990, pp 77-98.
154. Terstappen L, Loken M: Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Path 2:229-240, 1990.
155. Terstappen L, Safford M, Konemann S, Loken M. Zurlutter K, Buchner T, Hiddemann W, Wormann B: Flow cytometric characterization of acute myeloid leukemia Part II. Phenotypic heterogeneity at diagnosis. Leukemia 6:70-80, 1992.
156. Thakhi A, Edinger M, Myles J, Pohlman B, Tubbs R: Flow cytometric immunophenotyping of non-Hodgkin's lymphoma and related disorders. Cytometry 25:113-124, 1996.
157. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of Non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.
158. Thomas X, Campos L, Archimbaud E, Shi ZH, Treille-Ritovet D, Anglaret B, Fierc D: Surface marker expression in acute myeloid leukemia at first relapse. Br J Haematol 81:40-44, 1992.
159. Uckun F, Kersey J, Haake R, Weisdorf D, Nesbit M, Ramsay N: Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. New Engl J Med 329:1296, 1993
160. Urbano-Ispizua A, Cervantes F, Matutes E, Villamor N, Pujades A, Sierra J, Feliu E, Vives-Corrons JL, Montserrat E, Rozman C: Immunophenotypic characteristics of blast crisis of chronic myeloid leukemia. Leukemia 7:1349-1354, 1993.
161. Van De Ven H, Delbecq A: The effectiveness of nominal, Delphi, and interacting group decision making processes. Acad Management J 17:605-612, 1974.
162. Van Dongen J, Breit T, Adriaansen H, Beishizen A, Hooijkaas U: Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 6:47, 1992.
163. Visser J, Shaw A, Slupsky J, Poppema V: Monoclonal antibodies reactive with hairy cell leukemia. Blood 74:320-325, 1989.
164. Vuillier F, Claisse J, Vandenvelde C, Travade P, Magnac C, Chevret S, Desablens B, Binet J, Dighiero G: Evaluation of Residual Disease in B-Cell Chronic Lymphocytic Leukemia Patients in Clinical and Bone-Marrow Remission Using CD5-CD19 Markers and PCR Study of Gene Rearrangements. Leuk Lymphoma 7:195-204, 1992.
165. Ware R, Rosse W, Hall S: Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood 86:1586-1589, 1995.
166. Weaver C, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969, 1995.
167. Willman C: Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 10:S33-S35, 1996.
168. Witzig T, Banks P, Stenson M, Gripp P, Katzmann J, Habermann T, Colgan J: Rapid immunotyping of B-cell non-Hodgkin's lymphoma by flow cytometry. A comparision with standard frozen-section method. Am J Clin Pathol 94:280-286, 1990.
169. Witzig T, Kimlinger T, Ahmann G, Katzmann J, Greipp P: Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26:113-120, 1996.
170. Wognum A, Krystal G, Eaves C, Eaves A, Lansdorp P: Increased erythropoietin receptor expression on CD34 positive hone marrow cells from patients with chronic myeloid leukemia. Blood 79:642-649, 1992.
171. Yamada Y: Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood 62:192-199, 1988.
172. Zander D, Iturraspe J, Everett ET, Massey JK, Braylan RC: Flow cytometry: In vitro assessment of its potential application for diagnosis and classification of lymphoid processes in cytologic preparations from line-needle aspirates Am J Clin Pathol 101:577-586, 1994.
173. Zhang R, Yao E: Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia. Chin Med J 10:826-830, 1990.
174. Zukerberg L, Medeiros L, Ferry J, Harris N: Diffuse low-grade B-cell lymphomas: Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features Am J Clin Pathol 100:373-385, 1993.
175. Zupo S, lnsnardi L, Megna M, Massant R, Malavasi F, Dono M, Cosulich E, Ferrarini M: CD38 expression distinquishes two groups of B-cell chronic lymphocytic leukemia with different responses to anti-IgM antibodies and propensity to apoptosis Blood 88:1365-1374, 1996.